Cart (0 Items)
Your cart is currently empty.
View ProductsIt looks like you are visiting from outside the EU. Switch to the US version to see local pricing in USD and local shipping.
Switch to US ($)
| Size | 100ug, 1MG |
|---|---|
| Isotype | IgG4-nd |
| Brand | ProteoGenix |
| Product type | Primary Antibodies |
| Clonality | Monoclonal Antibody |
| Expression system | Mammalian cells |
| Applications | Elisa, WB |
| Product name | Reslizumab Biosimilar - Anti-IL5 mAb - Research Grade |
|---|---|
| Source | CAS 241473-69-8 |
| Species | Humanized |
| Expression system | Mammalian cells |
| Purity | >85% |
| Buffer | PBS buffer PH7.5 |
| Delivery condition | Blue ice (+4°C) |
| Delivery Time | 3-5 days if in stock; 3-5 weeks if production needed |
| Storage condition | store at -80°C |
| Brand | ProteoGenix |
| Aliases /Synonyms | Reslizumab,CDP-835,JES1-39D10,SCH55700,IL5,anti-IL5 |
| Reference | PX-TA1198 |
| Note | For research use only. Not suitable for clinical or therapeutic use. |
| Isotype | IgG4-nd |
| Clonality | Monoclonal Antibody |
Reslizumab is a humanized interleukin 5 (IL-5) antagonist monoclonal antibody (IgG4 kappa), produced by recombinant DNA technology in murine non-secretory myeloma 0 (NS0) cells. IL-5 is a pro-inflammatory cytokine responsible for the growth and differentiation, recruitment, activation and survival of eosinophil markers. Elevated levels of eosinophils increase the risk of exacerbation of asthma, including allergic and non-allergic forms of asthma characterized by eosinophilia. By targeting IL-5 and disrupting its signaling pathway, reslizumab aims to inhibit the maturation of eosinophils and promote programmed cell death. Reslizumab is sold as Cinqaero in Europe.
Related products
Got a question or need a quote?
Message us and we’ll get back to you 48 hours or less.
Reviews
There are no reviews yet.